Cargando…
Therapeutic antibody targeting of Notch3 signaling prevents mural cell loss in CADASIL
Cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is a neurological syndrome characterized by small vessel disease (SVD), stroke, and vascular cognitive impairment and dementia caused by mutations in NOTCH3. No therapies are available for this condi...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5551569/ https://www.ncbi.nlm.nih.gov/pubmed/28698285 http://dx.doi.org/10.1084/jem.20161715 |
_version_ | 1783256325429395456 |
---|---|
author | Machuca-Parra, Arturo I. Bigger-Allen, Alexander A. Sanchez, Angie V. Boutabla, Anissa Cardona-Vélez, Jonathan Amarnani, Dhanesh Saint-Geniez, Magali Siebel, Christian W. Kim, Leo A. D’Amore, Patricia A. Arboleda-Velasquez, Joseph F. |
author_facet | Machuca-Parra, Arturo I. Bigger-Allen, Alexander A. Sanchez, Angie V. Boutabla, Anissa Cardona-Vélez, Jonathan Amarnani, Dhanesh Saint-Geniez, Magali Siebel, Christian W. Kim, Leo A. D’Amore, Patricia A. Arboleda-Velasquez, Joseph F. |
author_sort | Machuca-Parra, Arturo I. |
collection | PubMed |
description | Cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is a neurological syndrome characterized by small vessel disease (SVD), stroke, and vascular cognitive impairment and dementia caused by mutations in NOTCH3. No therapies are available for this condition. Loss of mural cells, which encompass pericytes and vascular smooth muscle cells, is a hallmark of CADASIL and other SVDs, including diabetic retinopathy, resulting in vascular instability. Here, we showed that Notch3 signaling is both necessary and sufficient to support mural cell coverage in arteries using genetic rescue in Notch3 knockout mice. Furthermore, we show that systemic administration of an agonist Notch3 antibody prevents mural cell loss and modifies plasma proteins associated with Notch3 activity, including endostatin/collagen 18α1 and Notch3 extracellular domain in mice with the C455R mutation, a CADASIL variant associated with Notch3 loss of function. These findings open opportunities for the treatment of CADASIL and other SVDs by modulating Notch3 signaling. |
format | Online Article Text |
id | pubmed-5551569 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | The Rockefeller University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-55515692018-02-07 Therapeutic antibody targeting of Notch3 signaling prevents mural cell loss in CADASIL Machuca-Parra, Arturo I. Bigger-Allen, Alexander A. Sanchez, Angie V. Boutabla, Anissa Cardona-Vélez, Jonathan Amarnani, Dhanesh Saint-Geniez, Magali Siebel, Christian W. Kim, Leo A. D’Amore, Patricia A. Arboleda-Velasquez, Joseph F. J Exp Med Research Articles Cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is a neurological syndrome characterized by small vessel disease (SVD), stroke, and vascular cognitive impairment and dementia caused by mutations in NOTCH3. No therapies are available for this condition. Loss of mural cells, which encompass pericytes and vascular smooth muscle cells, is a hallmark of CADASIL and other SVDs, including diabetic retinopathy, resulting in vascular instability. Here, we showed that Notch3 signaling is both necessary and sufficient to support mural cell coverage in arteries using genetic rescue in Notch3 knockout mice. Furthermore, we show that systemic administration of an agonist Notch3 antibody prevents mural cell loss and modifies plasma proteins associated with Notch3 activity, including endostatin/collagen 18α1 and Notch3 extracellular domain in mice with the C455R mutation, a CADASIL variant associated with Notch3 loss of function. These findings open opportunities for the treatment of CADASIL and other SVDs by modulating Notch3 signaling. The Rockefeller University Press 2017-08-07 /pmc/articles/PMC5551569/ /pubmed/28698285 http://dx.doi.org/10.1084/jem.20161715 Text en © 2017 Machuca-Parra et al. http://www.rupress.org/terms/https://creativecommons.org/licenses/by-nc-sa/4.0/This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/). |
spellingShingle | Research Articles Machuca-Parra, Arturo I. Bigger-Allen, Alexander A. Sanchez, Angie V. Boutabla, Anissa Cardona-Vélez, Jonathan Amarnani, Dhanesh Saint-Geniez, Magali Siebel, Christian W. Kim, Leo A. D’Amore, Patricia A. Arboleda-Velasquez, Joseph F. Therapeutic antibody targeting of Notch3 signaling prevents mural cell loss in CADASIL |
title | Therapeutic antibody targeting of Notch3 signaling prevents mural cell loss in CADASIL |
title_full | Therapeutic antibody targeting of Notch3 signaling prevents mural cell loss in CADASIL |
title_fullStr | Therapeutic antibody targeting of Notch3 signaling prevents mural cell loss in CADASIL |
title_full_unstemmed | Therapeutic antibody targeting of Notch3 signaling prevents mural cell loss in CADASIL |
title_short | Therapeutic antibody targeting of Notch3 signaling prevents mural cell loss in CADASIL |
title_sort | therapeutic antibody targeting of notch3 signaling prevents mural cell loss in cadasil |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5551569/ https://www.ncbi.nlm.nih.gov/pubmed/28698285 http://dx.doi.org/10.1084/jem.20161715 |
work_keys_str_mv | AT machucaparraarturoi therapeuticantibodytargetingofnotch3signalingpreventsmuralcelllossincadasil AT biggerallenalexandera therapeuticantibodytargetingofnotch3signalingpreventsmuralcelllossincadasil AT sanchezangiev therapeuticantibodytargetingofnotch3signalingpreventsmuralcelllossincadasil AT boutablaanissa therapeuticantibodytargetingofnotch3signalingpreventsmuralcelllossincadasil AT cardonavelezjonathan therapeuticantibodytargetingofnotch3signalingpreventsmuralcelllossincadasil AT amarnanidhanesh therapeuticantibodytargetingofnotch3signalingpreventsmuralcelllossincadasil AT saintgeniezmagali therapeuticantibodytargetingofnotch3signalingpreventsmuralcelllossincadasil AT siebelchristianw therapeuticantibodytargetingofnotch3signalingpreventsmuralcelllossincadasil AT kimleoa therapeuticantibodytargetingofnotch3signalingpreventsmuralcelllossincadasil AT damorepatriciaa therapeuticantibodytargetingofnotch3signalingpreventsmuralcelllossincadasil AT arboledavelasquezjosephf therapeuticantibodytargetingofnotch3signalingpreventsmuralcelllossincadasil |